Immuno-therapyTrial

I thought I would just post this and maybe some readers or someone they know may be interested or need it as an option.

PDS Biotech is developing a new immuno-therapy designed to target HPV-16 called PDS0101. PDS0101 has been shown to stimulate high levels of HPV-16-specific killer T-cells that target and kill head and neck tumor cells that are caused by HPV-16 infection. We’re currently enrolling patients in VERSATILE-002, a clinical trial studying PDS0101 in combination with the checkpoint inhibitor KEYTRUDA (pembrolizumab). The study is for patients with HPV16-positive head and neck cancer that has returned or spread. While KEYTRUDA is an effective medication, it does not treat the HPV infection causing the cancer. Every patient who enrolls in VERSATILE-002 will be treated with both therapies.

Here is the link to the page at head & Neck.org  https://www.headandneck.org/hpv-attributed-head-and-neck-cancer-a-new-treatment-on-the-horizon/?eType=EmailBlastContent&eId=fbd35b28-c652-46fa-90ca-04088003c033

At the bottom of the article, there are a couple of things to click on that takes you to PDS Biotech website to see if you qualify. This may be an option for folks that traditional therapy has worked for or not and your cancer has spread or returned. These trials I believe are valuable to help in this fight. Take Care-God Bless-Russ